Lung cancer incidence statistics. Cancer Research UK http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/incidence (2014). Liu, J., Cheng, Y., Li, H. & Zhang, S. Current status of small cell lung cancer in China. J. Cancer Biol. ...
: Stage III unresectable locally advanced non-small cell lung cancer (NSCLC) is a complex disease group with poor long-term survival. Clinical data suggests curative intent concurrent chemoradiotherapy (CCRT) is superior to a sequential (SCRT) approach but comes with additional toxicities. We report...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
Six main representative therapeutically tractable targets in small-cell lung cancer (SCLC).aCell cycle and DNA damage repair pathways. PARP poly (ADP)-ribose polymerase, AURKA Aurora A kinase, CHK1 checkpoint kinase 1, ATR Ataxia telangiectasia and rad3 related, RS replication stress.bMetabolism a...
Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have improved outcomes markedly over the past two decades. However, the vast majority of adv
Abbreviations: KQ = key question; LS = limited-stage; SBRT = stereotactic body radiation therapy; SCLC = small cell lung cancer. What is the role of SBRT compared with conventional RT in stage I or II node negative SCLC? SBRT, a strategy that employs very high ablative doses of radiation...
The insulin-like growth factor pathway in lung cancer. J Thorac Oncol. 2008;3:815–8. Article PubMed Google Scholar Scagliotti GV, Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev. 2012;38:292...
Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan;66(1):7–30. 2. Ni J, Zhang L. Progress in treatment of Non-Small Cell Lung Cancer Harboring HER2 aberrations. OncoTargets Ther. 2021 Jul;14:4087–98. 3. ALQudah MA, ALFaqih MA, Hamouri S, Al-Shaikh AF, Haddad HK, Al-Quran...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose...
Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and transcriptomic heterogeneity. Subtypes based upon predominant transcription factor expression have been defined that, in mouse models and cell lines, exhibit potential differential therapeutic vulnerabilities, with epigenetically distin...